We also assessed PAK1 expression in association with clinicopathological parameters, including the EGFR mutation status, recurrence-free survival, and five-year survival of 201 patients with banked NSCLC tissue specimens using tissue microarray (TMA) analysis. Here, PAK1 is linked to non-small cell lung carcinoma.